Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15967647 | 1.00 | NPSR1 (0.39) | NPSR1MAPTMEN1KMT2ACYP3A4 | |
| Hydrochloric Acid SCHEMBL15967648 | 1.00 | NPSR1 (0.39) | NPSR1MAPTMEN1KMT2ACYP3A4 | |
| SCHEMBL10039814 | 0.98 | NPSR1 (0.41) | NPSR1MAPTMEN1KMT2ACYP3A4 | |
| SCHEMBL359078 | 0.98 | NPSR1 (0.41) | NPSR1MAPTMEN1KMT2ACYP3A4 | |
| SCHEMBL2972762 | 0.98 | NPSR1 (0.41) | NPSR1MAPTMEN1KMT2ACYP3A4 | |
| Hydrochloric Acid SCHEMBL17392829 | 0.94 | NPSR1 (0.42) | NPSR1MAPTMEN1KMT2ACYP3A4 | |
| SCHEMBL16068191 | 0.92 | NPSR1 (0.44) | NPSR1MAPTMEN1KMT2ACYP3A4 | |
| Hydrochloric Acid SCHEMBL11294912 | 0.91 | NPSR1 (0.38) | NPSR1MAPTMEN1KMT2ACYP3A4 | |
| Hydrochloric Acid SCHEMBL11294917 | 0.91 | NPSR1 (0.38) | NPSR1MAPTMEN1KMT2ACYP3A4 | |
| SCHEMBL11954281 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4660303-A2 | PCSK9 ANTAGONIST COMPOUNDS | Merck Sharp & Dohme LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250367192-A1 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | NEUREN PHARMACEUTICALS LTD (NZ) | 2025-12-04 | — | — | US | disclosed |
| US-12472177-B2 | Bicyclic compounds and methods for their use in treating Pitt Hopkins syndrome | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2025-11-18 | — | — | US | disclosed |
| EP-3810626-B1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250206781-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-06-26 | — | — | US | disclosed |
| US-12209145-B2 | PCSK9 antagonist compounds | MERCK SHARP & DOHME LLC (US) | 2025-01-28 | — | — | US | disclosed |
| US-12178842-B2 | PCSK9 antagonist compounds | MERCK SHARP & DOHME LLC (US) | 2024-12-31 | — | — | US | disclosed |
| WO-2024215870-A2 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF POLYMERASE THETA AND METHODS OF USE THEREOF | 1CBIO, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| EP-4374877-A2 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-29 | — | — | EP | disclosed |
| US-20240132511-A1 | TREATMENTS OF PRADER-WILLI SYNDROME | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2024-04-25 | — | — | US | disclosed |
| WO-2008063311-A2 | CYCLIC GLYCYL-2-ALLYL PROLINE IMPROVES COGNITIVE PERFORMANCE IN IMPAIRED ANIMALS | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2008-05-29 | — | — | WO | disclosed |
| EP-1888618-A2 | ANALOGS OF GLYCYL-PROLYL-GLUTAMATE | Neuren Pharmaceuticals Limited (NZ) | 2008-02-20 | — | — | EP | disclosed |
| US-20070298009-A1 | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2007-12-27 | — | — | US | disclosed |
| US-20070197511-A1 | Neuroprotective bicyclic compouds and methods for their use | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2007-08-23 | — | — | US | disclosed |
| US-20070004641-A1 | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2007-01-04 | — | — | US | disclosed |
| WO-2006127702-A2 | ANALOGS OF GLYCYL-PROLYL-GLUTAMATE | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2006-11-30 | — | — | WO | disclosed |
| US-20060258663-A1 | Cyclic G-2AllylProline in treatment of Parkinson's disease | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2006-11-16 | — | — | US | disclosed |
| US-20060251649-A1 | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2006-11-09 | — | — | US | disclosed |
| EP-1664050-A2 | NEUROPROTECTIVE BICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Neuren Pharmaceuticals Limited (NZ) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005023815-A2 | NEUROPROTECTIVE BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367192-A1 | BICYCLIC COMPOUNDS AND METHODS FOR THEIR USE IN TREATING PITT HOPKINS SYNDROME | QPCT, GRIA2, GGPS1 | PARP1 3855/4885NPSR1 540/4885MAPT 309/4885 |
| US-20240132511-A1 | TREATMENTS OF PRADER-WILLI SYNDROME | COMT, HSD17B3, HSD3B1 | PARP1 1314/4885NPSR1 41/4885MAPT 3291/4885 |
| US-20070298009-A1 | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration | GRM2, GRM1, GLUL | PARP1 1373/4885NPSR1 810/4885MAPT 545/4885 |
| US-12178842-B2 | PCSK9 antagonist compounds | PCSK9, PCSK7, PCSK6 | PARP1 984/4885NPSR1 547/4885MAPT 2411/4885 |
| US-20060251649-A1 | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate | GRM2, GRIN2C, GRIN2A | PARP1 1444/4885NPSR1 1486/4885MAPT 2325/4885 |
| US-12209145-B2 | PCSK9 antagonist compounds | PCSK9, PCSK7, PCSK6 | PARP1 1017/4885NPSR1 341/4885MAPT 4060/4885 |
| US-20070197511-A1 | Neuroprotective bicyclic compouds and methods for their use | NLN, GAP43, BAD | PARP1 120/4885NPSR1 787/4885MAPT 479/4885 |
| US-12472177-B2 | Bicyclic compounds and methods for their use in treating Pitt Hopkins syndrome | QPCT, GRIA2, GGPS1 | PARP1 3855/4885NPSR1 540/4885MAPT 309/4885 |
| US-20060258663-A1 | Cyclic G-2AllylProline in treatment of Parkinson's disease | PARK7, ADCYAP1R1, LRRK2 | PARP1 994/4885NPSR1 613/4885MAPT 971/4885 |
| US-20070004641-A1 | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate | CHAT, GAP43, BCHE | PARP1 3092/4885NPSR1 955/4885MAPT 207/4885 |
| US-20250206781-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | PARP1 1017/4885NPSR1 341/4885MAPT 4060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.